Can-Fite BioPharma Ltd.

Can-Fite BioPharma Ltd. is a biopharmaceutical company, which engages in the development of drugs for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. Its product pipeline include Piclidenoson, Namodenoson, and CF602. The company was founded by Pnina Fishman and Ilan Cohn on September 11, 1994 and is headquartered in Petach-Tikva, Israel.

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite's Namodenoson Abstract Selected as ‘Best of The Liver Meeting ‘ in the NASH Category of the American Association of Liver Diseases (AASLD)

Can-Fite's Namodenoson Abstract Selected as ‘Best of The Liver Meeting' in the NASH Category of the American Association of Liver Diseases (AASLD)

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET

Can-Fite to Conduct Investor Call to Review Q3 Results and Provide Business Update on Monday, November 30, 2020 at 9:15 a.m. ET

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of AASLD Conference

Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference

Five Prime Therapeutics

GT Biopharma Inc

InflaRx

Tonix Pharmaceuticals Hld

vTv Therapeutics

Vaxart

With the pandemic drawing much attention toward biotech stocks, there are some interesting ideas among in the small-cap field, but only if you understand the severe risks involved. The post 7 Biotech Penny Stocks Worth a Gamble appeared first on InvestorPlace.

7 Biotech Penny Stocks Worth a Gamble

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020

Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020

Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that the Independent Data Monitoring Committee (IDMC) which conducted an interim analysis of the Company’s Phase III Comfort™ trial of Piclidenoson in the treatment of moderate-to-severe plaque psoriasis, recommended, based on the positive data, to c

Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Selected to Deliver Late-Breaking Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases

Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Participate in Two BioPharma Partnering Conferences

Can-Fite to Participate in Two BioPharma Partnering Conferences

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

PETACH TIKVA, Israel--(BUSINESS WIRE)--FDA Clears Can-Fite to Commence Phase II COVID-19 Study

FDA Clears Can-Fite to Commence Phase II COVID-19 Study

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q2 2020 Results - Earnings Call Transcript

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced financial results for the six months ended June 30, 2020.

Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH

Can-Fite Receives Notification of Patent Grant from European Patent Office for Namodenoson in the Treatment of NASH

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET

Can-Fite to Conduct Investor Call to Review Q2 Results and Provide Business Update on Thursday, August 27, 2020 at 4:15 p.m. ET

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study

Can-Fite Submits Investigational New Drug Application to U.S. FDA for COVID-19 Phase II Study

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds

Can-Fite Completes Development of an Assay to Identify Clinically Active Cannabis Derived Compounds

PETACH TIKVA, Israel--(BUSINESS WIRE)--Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly

Can-Fite Completes Phase II COVID-19 Protocol Based on FDA Guidance, Plans to File IND Shortly

Can-Fite BioPharma Ltd. (CANF) CEO Pnina Fishman on Q1 2020 Results - Earnings Call Transcript

Athersys

BioCryst Pharmaceuticals

Biocept

As the COVID-19 pandemic continues to ravage the globe, having claimed over 115,000 lives, health care companies have are pursuing diagnostics tests, potential vaccines and therapies.

Biocept To Begin COVID-19 Testing Wednesday, BioCryst, Athersys, Can-Fite To Research Potential Treatments In Clinics

Can-Fite BioPharma (NYSE: CANF) shares were trading higher on Tuesday, after the company announced it achieved its main study endpoint in phase 2 NASH study with Namodenoson were dose-dependent.

Why Can-Fite's Stock Is Moving Higher Today

Aytu BioScience

Enanta Pharmaceuticals

La Jolla Pharmaceutical

Eli Lilly

OPKO Health

Roche Holding AG

The following are the latest biotech announcements from late Thursday and Friday morning on the development of products targeting the coronavirus.

The Latest Coronavirus Developments From Biotechs: La Jolla Provides Giapreza In Italy, Enanta Researches Antivirals

Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.

Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment

PETACH TIKVA, Israel, Feb.  10, 2020  (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and inflammatory diseases, today announced the pricing of a public offering of 3,333,334 units at a price to the public of $1.50 per unit. The Company expects to receive aggregate gross proceeds of approximately $5.0 million from the offering, before deducting the placement agent fees and estimated offering expenses. Each unit is comprised of one American Depositary Share (ADS) (or ADS equivalent) and one warrant to purchase one ADS at an exercise price of 1.50 per ADS. The warrants are immediately exercisable upon issuance and have a term of five years. Each ADS represents 30 ordinary shares of the Company. The ADSs (or ADS equivalents) and the accompanying warrants included in the units can only be purchased together in this offering, but will be issued separately and will be immediately separable upon issuance.

Can-Fite BioPharma Announces Pricing of $5 Million Public Offering

Can-Fite BioPharma Ltd 
CANF 3.77%
, an Israeli biotechnology company with a pipeline of proprietary compounds in Phase 2 and 3 clinical development stage that address autoimmune-inflammatory and cancer diseases, last week disclosed that CEO of Univo Pharmaceuticals, Golan Bitton, was elected as a board member to Can-Fite at its recent annual general meeting.

News for Can-Fite BioPharma Ltd. Stock (CANF)